Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma-Reference-Cited by-同舟云学术

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma

Published:2019-02 Issue:1 Volume:17 Page:1-6
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Msaouel Pavlos^ORCID,Hong Andrew L.,Mullen Elizabeth A.,Atkins Michael B.,Walker Cheryl Lyn,Lee Chung-Han^ORCID,Carden Marcus A.,Genovese Giannicola,Linehan W. Marston,Rao Priya^ORCID,Merino Maria J.,Grodman Howard,Dome Jeffrey S.,Fernandez Conrad V.^ORCID,Geller James I.,Apolo Andrea B.,Daw Najat C.,Hodges H. Courtney^ORCID,Moxey-Mims Marva,Wei Darmood,Bottaro Donald P.,Staehler Michael,Karam Jose A.,Rathmell W. Kimryn^ORCID,Tannir Nizar M.

Funder

Johnson Foundation

Kidney Cancer Association

National Institutes of Health

Conquer Cancer Foundation

Cancer Prevention Research Institute of Texas (CPRIT)

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference44 articles.

1. Renal medullary carcinoma. The seventh sickle cell nephropathy;Davis;Am J Surg Pathol,1995